carbamates has been researched along with bms-650032 in 188 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 173 (92.02) | 24.3611 |
| 2020's | 15 (7.98) | 2.80 |
| Authors | Studies |
|---|---|
| Chayama, K; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Takahashi, S; Toyota, J; Watanabe, H | 1 |
| Suk-Fong Lok, A | 1 |
| Chayama, K; Hernandez, D; Ikeda, K; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Suzuki, F; Toyota, J; Watanabe, H; Yu, F | 1 |
| Chayama, K; Eley, T; Hu, W; Hughes, E; Ikeda, K; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Suzuki, F; Suzuki, Y; Toyota, J; Watanabe, H | 1 |
| Bukh, J; Ghanem, L; Gottwein, JM; Jensen, SB; Li, YP; Mikkelsen, L; Scheel, TK; Serre, SB | 1 |
| Chaniewski, S; Chen, C; Friborg, J; Lemm, JA; Levine, S; McPhee, F; Sheaffer, AK; Voss, S | 1 |
| Forns, X; Lens, S; Londoño, MC | 1 |
| Carifa, A; Eley, T; Falk, P; Fridell, R; Gardiner, D; Hernandez, D; McPhee, F; Monikowski, A; Ueland, J; Wang, C; Yu, F; Zhou, N | 1 |
| Aghemo, A; Colombo, M | 1 |
| Bourlière, M; Chung, E; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, E; Loustaud-Ratti, V; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Tatum, H; Thuluvath, PJ; Wang, X; Wind-Rotolo, M | 1 |
| Friedman, SL | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Bourlière, M; Eley, T; Everson, GT; Gardiner, DF; Grasela, DM; Hézode, C; Huang, SP; Lawitz, EJ; Li, J; Lok, AS; Marcellin, P; McPhee, F; Pasquinelli, C; Pol, S; Rodriguez-Torres, M; Serfaty, L; Wind-Rotolo, M; Yu, F | 1 |
| Chayama, K; Damokosh, A; Eley, T; Hughes, E; Ido, A; Ikeda, K; Ishikawa, H; Izumi, N; Karino, Y; Kawada, N; Kawakami, Y; Koike, K; Kumada, H; McPhee, F; Miyagoshi, H; Sata, M; Suzuki, Y; Takaguchi, K; Takehara, T; Toyota, J; Yamamoto, K | 1 |
| Chiba, K; Fu, Z; Furihata, T; Kobayashi, K; Matsumoto, S; Sun, Y; Tsubota, A | 1 |
| Adler, H; Lambert, JS | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Inaba, T; Kanai, A; Kawaoka, T; Kosaka, K; Matsui, H; Miki, D; Murakami, E; Ochi, H; Tsuge, M; Yoshimi, S | 1 |
| Bourliere, M; Bronowicki, JP; Chang, TT; Chu, CJ; Everson, GT; Gerken, G; Gordon, SC; Heo, J; Hughes, E; Jacobson, IM; Kao, JH; Kopit, J; Lee, YJ; Linaberry, M; Manns, M; Marcellin, P; McPhee, F; Mendez, P; Metivier, S; Noviello, S; Peng, CY; Pol, S; Sievert, W; Thabut, D; Towner, WJ; Yoffe, B | 1 |
| Gane, E | 1 |
| Bertz, R; Bifano, M; Eley, T; Gardiner, D; Grasela, DM; He, B; Huang, SP; Kandoussi, H; Sevinsky, H; Zhu, K | 1 |
| Poole, RM | 1 |
| Fujii, Y; Mochida, S; Uchida, Y | 1 |
| Bennett, M; Chung, E; Gardiner, DF; Gitlin, N; Grasela, DM; Griffies, A; Hassanein, T; Lawitz, E; McPhee, F; Nguyen, T; Rege, B; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Wind-Rotolo, M; Younossi, Z; Zhou, H; Zhou, N | 1 |
| Arnold, ME; Aubry, AF; Baker, C; Burrell, R; Cojocaru, L; Demers, R; Easter, J; Eley, T; He, B; Jiang, H; Kadiyala, P; Kandoussi, H; Pursley, J; Ryan, J; Wang, J; Zeng, J | 1 |
| Bernstein, D; Brunetto, M; de Ledinghen, V; Elkhashab, M; Everson, G; Hennicken, D; Heo, J; Hézode, C; Hughes, E; Jensen, D; Kugelmas, M; Luketic, V; Mauss, S; McPhee, F; Mendez, P; Noviello, S; Pol, S; Serfaty, L; Sherman, KE; Tran, A; Vierling, J; Younes, ZH; Zeuzem, S | 1 |
| Bertz, RJ; Bifano, M; Eley, T; Hiraoka, M; Nagashima, H; Shiozaki, T; Ueno, T; Yamahira, N | 1 |
| Suzuki, F | 2 |
| Amano, M; Ishikawa, H | 1 |
| Conjeevaram, H | 1 |
| Angus, P; Bennett, M; Boparai, N; Boyer, N; Bräu, N; Bronowicki, JP; Conway, B; de Lédinghen, V; Hughes, E; Jacobson, I; Lee, SS; Levin, J; McPhee, F; Mollison, L; Muir, AJ; Ortiz-Lasanta, G; Pol, S; Poordad, F; Reddy, KR; Sepe, T; Sievert, W; Sulkowski, M; Swenson, ES; Tam, E; Tse, E; Yin, PD | 1 |
| Cooper, J; Dore, GJ; Everson, G; Freilich, B; Ghesquiere, W; Herring, R; Hézode, C; Hughes, EA; Kwo, P; Lalezari, J; McPhee, F; Muir, AJ; Pockros, PJ; Poordad, F; Ramji, A; Reau, N; Sheikh, A; Stuart, K; Swenson, ES; Thompson, AJ; Tran, A; Vierling, J; Yang, R; Yin, PD; Yozviak, J | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Kawakami, Y; Murakami, E; Ochi, H; Sasaki, T; Tsuge, M; Yoshimi, S | 1 |
| Bunchorntavakul, C; Reddy, KR | 1 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Ikeda, F; Iwasaki, Y; Kinugasa, H; Matsubara, T; Mori, C; Shiraha, H; Takaguchi, K; Takaki, A; Toyooka, S; Yamamoto, K | 1 |
| Ahn, SH; Bhore, R; Chayama, K; Hernandez, D; Ishikawa, H; Karino, Y; Kawakami, Y; Kumada, H; McPhee, F; Mendez, P; Suzuki, Y; Toyota, J; Yu, ML; Zhou, N | 1 |
| Behl, AS; Betts, KA; Kalsekar, A; Li, J; Signorovitch, JE; Song, Y; Sorg, RA | 1 |
| Hikita, H; Hiramatsu, N; Kai, Y; Morishita, N; Nakabori, T; Nawa, T; Oze, T; Saito, Y; Sakamori, R; Suemizu, H; Takehara, T; Tanaka, S; Tatsumi, T; Yakushijin, T | 1 |
| Boonstra, A; de Knegt, RJ; Hansen, BE; Hou, J; Janssen, HL; Kreefft, K; Spaan, M; van Oord, G | 1 |
| Boor, PP; de Jonge, J; de Ruiter, PE; Ijzermans, JN; Kwekkeboom, J; Metselaar, HJ; Tilanus, HW; van der Laan, LJ | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Hughes, E; Ishikawa, H; Ito, T; Itoh, Y; Karino, Y; Kawakami, Y; Kumada, H; Linaberry, M; McPhee, F; Suzuki, F; Suzuki, Y; Tamura, E; Toyota, J; Ueki, T | 1 |
| Ueda, Y; Uemoto, S | 1 |
| Akuta, N; Arase, Y; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Borgia, G; Buonomo, AR; Gentile, I; Scotto, R; Zappulo, E | 1 |
| Alkan, M; Balkan, II; Mete, B; Ozaras, R; Tabak, F; Yemisen, M | 1 |
| Akamatsu, N; Kokudo, N; Sugawara, Y | 1 |
| Barrail-Tran, A; Cheret, A; Furlan, V; Molina, JM; Piroth, L; Rosa, I; Rosenthal, E; Taburet, AM; Vincent, C | 1 |
| Hubbard, H; Lawitz, E; Vizuete, J | 1 |
| Desta, T; Eley, T; Everson, GT; Gardiner, DF; Gitlin, N; Grasela, DM; Hassanein, T; Hawkins, T; Hinestrosa, F; Huang, SP; Lawitz, E; Levin, JM; McPhee, F; Rodriguez-Torres, M; Rustgi, V; Schwartz, H; Sims, KD; Thuluvath, PJ; Webster, L; Younossi, Z | 1 |
| Burchill, MA; Golden-Mason, L; Rosen, HR; Wind-Rotolo, M | 1 |
| Kao, JH; Yang, SS | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, CL | 1 |
| Abe, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Miki, D; Miyaki, E; Ochi, H; Tateno, C; Tsuge, M; Uchida, T | 1 |
| Hatae, T; Hayashi, Y; Imoto, S; Kim, KI; Kim, SK; Kim, SR; Kudo, M; Ohtani, A; Sugimoto, K; Tohyama, M; Yano, Y | 1 |
| Bessone, F; Bhore, R; Heo, J; Hughes, E; Jacobson, I; Jensen, DM; Kao, JH; Kumada, H; Lee, YJ; Manns, MP; Mendez, P; Noviello, S; Peng, CY; Roberts, SK; Sievert, W; Toyota, J; Yoffe, B | 1 |
| Ghany, M; Keane, M; Liang, TJ; O'Keefe, AC; Park, H; Rehermann, B; Rivera, E; Serti, E | 1 |
| Adie, SK; Rizza, SA; Temesgen, Z; Zeuli, JD | 1 |
| Furuya, K; Horimoto, H; Izumi, T; Kimura, M; Kobayashi, T; Konno, J; Kudo, M; Morikawa, K; Nagasaka, A; Nakai, M; Natsuizaka, M; Ogawa, K; Sakamoto, N; Sato, F; Shinada, K; Sho, T; Suda, G; Tateyama, M; Terashita, K; Tsukuda, Y; Tsunematsu, S; Umemura, M; Yamamoto, Y; Yamasaki, K | 1 |
| Kelley, C; McPhee, F; Signorovitch, J; Swallow, E; Wygant, G | 1 |
| Iio, E; Ishikawa, T; Kumada, T; Tada, T; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsuji, K; Zeniya, M | 1 |
| Adachi, K; Ishii, T; Kumon, D; Matsumoto, N; Noguchi, Y; Okuse, C; Sato, A; Tamura, T | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Pinchera, B; Scotto, R; Zappulo, E | 1 |
| Fukuda, Y; Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Matsumoto, N; Matsunaga, K; Noguchi, Y; Okuse, C; Sato, A; Shigefuku, R; Suzuki, M; Tamura, T; Watanabe, T | 1 |
| Bae, SH; Chen, X; Chuang, WL; Garimella, T; Gong, G; Jia, J; Jia, Z; Li, Y; Lin, S; Lu, W; McPhee, F; Mo, L; Niu, J; Torbeyns, A; Treitel, M; Wei, L; Xie, Q; Xie, W; Xu, M; Yang, YF; Yin, PD; Zhang, M | 1 |
| Ahn, SH; Bhore, R; Chang, TT; Heo, J; Hughes, E; Kao, JH; Lee, YJ; Lim, YS; Noviello, S; Peng, CY; Torbeyns, A | 1 |
| Miyagi, K; Miyazaki, R | 1 |
| Furuta, K; Kamada, T; Tomioka, H | 1 |
| Chang, SY; Cheng, Y; Humphreys, WG; Li, W; Ma, L | 1 |
| Abe, H; Atsukawa, M; Eguchi, Y; Fujiwara, K; Hasegawa, I; Hirashima, N; Iio, E; Kang, JH; Kuramitsu, T; Kusakabe, A; Matsui, T; Miyaki, T; Nojiri, S; Nomura, H; Shimada, N; Shinkai, N; Takaguchi, K; Tanaka, Y; Tsubota, A; Yoshizawa, K | 1 |
| Arai, M; Haga, Y; Imazeki, F; Kanda, T; Nakamoto, S; Nakamura, M; Sasaki, R; Suzuki, E; Wu, S; Yasui, S; Yokosuka, O | 1 |
| Hernandez, D; Huang, X; Kirov, S; McPhee, F; Pant, S; Yu, F | 1 |
| Tanaka, Y | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Kuzuya, T; Nishimura, D | 1 |
| Hattori, N; Hiraishi, T; Ikeda, H; Ishii, T; Itoh, F; Izumi, N; Kobayashi, M; Kurosaki, M; Matsumoto, N; Matsunaga, K; Nakano, H; Okuse, C; Shigefuku, R; Suzuki, M; Watanabe, T; Yamada, N; Yamamoto, H; Yasuda, H; Yasuda, K; Yotsuyanagi, H | 1 |
| Lee, HL; Nam, HC; Song, MJ; Yang, H | 1 |
| Asahina, Y; Asano, Y; Azuma, S; Goto, F; Itsui, Y; Kakinuma, S; Kaneko, S; Kawai-Kitahata, F; Miyoshi, M; Murakawa, M; Nagata, H; Nakagawa, M; Nishimura-Sakurai, Y; Nitta, S; Otani, S; Tohda, S; Tojo, N; Tsunoda, T; Watanabe, M | 1 |
| Chayama, K; Fujiyama, S; Hu, W; Ido, A; Ikeda, F; Inada, Y; Ishikawa, H; Karino, Y; Kumada, H; Linaberry, M; McPhee, F; Naganuma, A; Suzuki, F; Swenson, ES; Takaguchi, K; Tanaka, K; Tomita, E; Toyota, J; Watanabe, H; Yin, PD; Yoshiji, H | 1 |
| Aikata, H; Chayama, K; Hayes, CN; Hiramatsu, A; Honda, Y; Imamura, M; Kawakami, Y; Kawaoka, T; Kobayashi, T; Makokha, GN; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Ochi, H; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S | 1 |
| Chayama, K; Hayes, CN | 1 |
| Chen, YP; Pi, SN | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawakami, Y; Kawaoka, T; Kimura, Y; Kobayashi, T; Miki, D; Mori, N; Morio, K; Morio, R; Nagaoki, Y; Nelson Hayes, C; Ochi, H; Takahashi, S; Takaki, S; Tsuge, M; Tsuji, K; Yokoyama, S | 1 |
| Abe, H; Aikata, H; Chayama, K; Chowdhury, S; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Makokha, GN; Miki, D; Ochi, H; Tateno, C; Tsuge, M; Uchida, T | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 2 |
| Hirashima, N; Ikeda, H; Imamura, J; Itoh, F; Iwase, H; Matsumoto, N; Okuse, C; Ryuge, N; Shimada, M; Tanaka, Y; Watanabe, T; Yokomaku, Y | 1 |
| Amemiya, M; Koshima, Y; Kuriyama, S; Maruyama, Y; Morisawa, N; Satoh, JI; Yokoo, T | 1 |
| Abe, T; Asahina, Y; Enomoto, N; Hasebe, C; Hisai, H; Ide, Y; Itakura, J; Izumi, N; Joko, K; Kobashi, H; Kurosaki, M; Mitsuda, A; Murakawa, M; Ogawa, C; Okushin, H; Osaki, Y; Sakita, S; Satou, T; Takaguchi, K; Tamada, T; Tsuji, K; Tsuruta, S; Yagisawa, H | 1 |
| Cao, Y; Huo, N; Lu, H; Wu, C; Xu, X; Zhang, R; Zhang, X; Zhang, Y | 1 |
| Hiraoka, A; Ishikawa, T; Kumada, T; Okanoue, T; Senoh, T; Shima, T; Shimada, N; Tachi, Y; Tada, T; Takaguchi, K; Toyoda, H; Tsuji, K | 1 |
| Bassit, L; Benhamou, Y; Chen, G; Chen, J; Hou, J; Hsiao, HM; Ji, D; Jiang, Y; Ke, R; Lau, G; Li, B; Li, F; Li, J; Liu, J; Perelson, AS; Schinazi, RF; Shao, Q; Sun, J; Tao, S; Tsang, ST; Wang, C; Wang, Y; Wong, A; Wong, CL; Wu, V | 1 |
| Chayama, K; Hayes, CN; Imamura, M | 1 |
| Flamm, S; Hughes, EA; Kayali, Z; Kwo, P; Lawitz, EJ; Linaberry, M; McPhee, F; Sulkowski, MS; Swenson, ES; Torbeyns, A; Yin, PD | 1 |
| Goto, H; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Kumada, T; Kuzuya, T; Nakano, I; Urano, F; Yoshioka, K | 3 |
| Gan, T; Lu, J; Tao, W; Zhong, J | 1 |
| Chen, PJ; Hong, CM; Liu, CJ; Yeh, SH | 1 |
| Fujisaka, Y; Inoue, J; Kakazu, E; Kanno, A; Kobayashi, T; Kogure, T; Miura, M; Morosawa, T; Nakamura, T; Ninomiya, M; Shimosegawa, T; Takai, S; Umetsu, T; Wakui, Y | 1 |
| Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Oshige, A; Saishoji, A; Sakae, H; Tabu, K; Tamai, T; Taniyama, O; Uto, H | 1 |
| Yu, ML | 1 |
| Hagiwara, H; Hikita, H; Hiramatsu, N; Iio, S; Imai, Y; Kai, Y; Kato, T; Kondo, Y; Morishita, N; Murai, K; Naito, M; Nakabori, T; Nishiuchi, M; Oze, T; Sakamori, R; Suemizu, H; Takehara, T; Tamura, S; Tatsumi, T; Tsutsui, S; Yakushijin, T; Yamada, R | 1 |
| Chae, HB; Cho, BW; Kang, YW; Kim, HS; Kim, SB; Kim, SH; Lee, BS; Lee, SH; Lee, TH; Song, IH | 1 |
| Hashinokuchi, S; Kataoka, S; Kumada, T; Mizuno, K; Sone, Y; Tada, T; Toyoda, H | 1 |
| Furuya, K; Iio, E; Ito, J; Izumi, T; Katagiri, M; Kawagishi, N; Kimura, M; Konno, J; Kumagai, K; Morikawa, K; Nakai, M; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Tanaka, Y; Tsubota, A; Umemura, M; Yamamoto, Y | 1 |
| Endo, T; Murakami, R; Nakamura, M; Nakamura, N; Narita, I; Shimada, M; Tomita, H; Yamabe, H | 1 |
| Inuzuka, T; Marusawa, H; Nasu, A; Osaki, Y; Sekine, A; Seno, H; Takeda, H; Takemura, R; Ueda, Y; Umeda, M; Yamashita, Y | 1 |
| Ahn, SH; Chang, TT; Chu, CJ; Heo, J; Hu, TH; Hu, W; Isakov, V; Kao, JH; Lee, YJ; Lim, YS; McPhee, F; Paik, SW; Peng, CY; Scott Swenson, E; Treitel, M; Yin, PD; Yoon, KT; Yu, ML | 1 |
| Aizawa, Y; Endo, D; Hokari, A; Satoh, K; Shimada, N | 1 |
| Goto, H; Hattori, M; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishikawa, T; Ishizu, Y; Katano, Y; Kawashima, H; Kuzuya, T; Tachi, Y | 1 |
| Enomoto, M; Hagihara, A; Hai, H; Kawada, N; Kawamura, E; Kozuka, R; Morikawa, H; Motoyama, H; Murakami, Y; Tamori, A; Teranishi, Y; Uchida-Kobayashi, S; Yoshida, K | 1 |
| Arataki, K; Chayama, K; Furusyo, N; Furuya, K; Hiraoka, A; Iio, E; Ikeda, H; Ishikawa, T; Katamura, Y; Kato, K; Kawakami, Y; Kudo, M; Kumada, T; Kurosaki, M; Mori, N; Morikawa, K; Nagasaka, A; Nakai, M; Ogawa, K; Sakamoto, N; Shimada, N; Sho, T; Suda, G; Suzuki, M; Takaguchi, K; Tanaka, Y; Toyoda, H; Tsuji, K; Ueno, Y; Yamamoto, Y; Yamsaki, S | 1 |
| Harada, S; Iida, T; Koshino, K; Masuda, K; Matsuyama, T; Nakamura, T; Nobori, S; Ushigome, H; Yoshimura, N | 1 |
| Chang, CS; Lee, SW; Lee, TY; Lu, IT; Yang, SS; Yeh, HZ | 1 |
| McEwan, P; Mishina, S; Wang, F; Ward, T; Webster, S; Wygant, G | 1 |
| Aikata, H; Chayama, K; Daijo, K; Fujino, H; Hatooka, M; Hayes, CN; Hiramatsu, A; Honda, F; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Masaki, K; Miki, D; Morio, K; Morio, R; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Ono, A; Teraoka, Y; Tsuge, M | 1 |
| Ida, Y; Iguchi, M; Kato, J; Kawashima, A; Kitano, M; Maekita, T; Moribata, K; Nakao, T; Shimizu, R; Shingaki, N; Taki, S; Tamai, H | 1 |
| Kim, JK; Lee, JI; Lee, KS; Yu, JH | 1 |
| Kim, HJ; Lee, HW; Won, JW; Yoo, KY | 1 |
| Akamatsu, N; Eguchi, S; Furukawa, H; Goto, R; Honda, M; Ikegami, T; Inomata, Y; Ishiyama, K; Kitagawa, Y; Kokudo, N; Ku, Y; Kuramitsu, K; Maehara, Y; Ohdan, H; Okajima, H; Shimada, M; Shinoda, M; Soyama, A; Taketomi, A; Ueda, Y; Uemoto, S; Yanaga, K; Yoshizumi, T | 1 |
| Ahmed, AM; Doheim, MF; Hirayama, K; Hoa, PTL; Huy, NT; Mattar, OM; Sherif, NA; Truong, DH | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kominami, Y; Kumada, H; Ogasawara, N; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Burchill, MA; Crochet, N; Dran, RJ; Edwards, MG; Gale, M; Kriss, MS; Roby, JA; Rosen, HR; Stone, AE; Wind-Rotolo, M | 1 |
| Arizumi, T; Chishina, H; Hagiwara, S; Ida, H; Kono, M; Kudo, M; Minami, T; Minami, Y; Nishida, N; Takita, M; Ueshima, K; Yada, N | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Amemiya, F; Asahina, Y; Enomoto, N; Fukasawa, M; Inoue, T; Kuratomi, N; Maekawa, S; Matsuda, S; Miura, M; Murakawa, M; Muraoka, M; Nakagawa, M; Nakakuki, N; Nakayama, Y; Sakamoto, M; Sato, M; Sato, T; Suzuki, Y; Takano, S; Tatsumi, A; Yamaguchi, T | 1 |
| Chida, T; Ito, J; Kawata, K; Kobayashi, Y; Matsunaga, E; Noritake, H; Ohta, K; Shimoyama, S; Suda, T; Suzuki, T; Yamazaki, S | 1 |
| Canini, L; Chayama, K; Cotler, SJ; Dahari, H; Imamura, M; Kawakami, Y; Uprichard, SL | 1 |
| Hidaka, H; Inoue, T; Koizumi, W; Kubota, K; Murakami, S; Nakatani, S; Nakazawa, T; Shibuya, A; Takeuchi, A; Tanaka, Y; Uojima, H; Yamane, K | 1 |
| Espinoza, MA; Giglio, A; Soza, A; Vargas, C | 1 |
| AbuTarif, M; Bhatnagar, R; Chang, YT; Eley, T; Garimella, T; LaCreta, F; Myers, E; Rana, J; Sims, K; Tao, X; Wind-Rotolo, M | 1 |
| Asselah, T; Bellissant, E; Bourlière, M; Bronowicki, JP; Canva, V; Diallo, A; Fontaine, H; Laforest, C; Leroy, V; Loustaud-Ratti, V; Ouzan, D; Petrov-Sanchez, V; Renault, A; Roulot, D; Rousseau, C; Schischmanoff, O; Serfaty, L; Thibault, V; Zoulim, F | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI | 1 |
| Asahina, A; Chihara, M; Kikuchi, S; Nakagawa, H; Umezawa, Y | 1 |
| Ahn, SH; Han, KH; Jeong, Y; Kim, BK; Kim, DY; Kim, S; Kim, SU; Lee, HW; Oh, SR; Park, JY | 1 |
| Lin, H; Liu, Y; Tobe, RG; Wang, Z; Wu, B | 1 |
| Akuta, N; Chayama, K; Fujiyama, S; Ido, A; Ikeda, F; Inada, Y; Ishikawa, H; Karino, Y; Kumada, H; McPhee, F; Naganuma, A; Noviello, S; Takaguchi, K; Tanaka, K; Tomita, E; Toyota, J; Watanabe, H; Yoshiji, H | 1 |
| Araki, N; Eguchi, Y; Iwane, S; Kawakubo, M; Koga, A; Nakashita, S; Oeda, S; Okada, M; Otsuka, T | 1 |
| Kakizaki, S; Kosone, T; Kusano, M; Sato, K; Suzuki, Y; Takagi, H; Takakusagi, S; Yamazaki, Y | 1 |
| Chang, F; Duan, CA; Jin, X; Lu, Y | 1 |
| Jung, J; Kirchner, VA; Kwon, JH; Lee, SG; Song, GW; Tak, EY | 1 |
| Alao, H; Cam, M; Fourie, NH; Ghany, MG; Henderson, WA; Keembiyehetty, C; Li, Q; Liang, TJ; Park, H; Rehermann, B; Serti, E; Suarez, D; Wright, EC; Zhang, F | 1 |
| Ahn, SH; Han, KH; Jeong, Y; Jin, B; Kim, DY; Kim, S; Lee, HW; Park, HJ; Park, JY | 1 |
| Chung, WJ; Hwang, JS; Jang, BK; Jang, SY; Kim, BS; Kwak, SG; Kweon, YO; Lee, CH; Lee, HJ; Oh, JY; Park, JG; Park, SY; Song, JE; Suh, JI; Tak, WY | 1 |
| Esposito, I; Marciano, S; Trinks, J | 1 |
| Chen, W; Gordon, J; Tan, MP; Wang, PF; Ward, T; Wygant, GD; Yan, J | 1 |
| Conway, B; Thiam, A | 1 |
| Bando, E; Hatanaka, N; Komoto, A; Nakamura, K; Suzuki, F | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Hayes, CN; Hiraga, N; Imamura, M; Ishida, Y; Kan, H; Makokha, GN; Miki, D; Ochi, H; Osawa, M; Saito, Y; Tateno, C; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Goto, H; Hattori, M; Hayashi, K; Hirooka, Y; Honda, T; Ishigami, M; Ishizu, Y; Katano, Y; Kumada, T; Kuzuya, T; Toyoda, H | 1 |
| Garimella, T; Imai, Y; Ishikawa, H; Osawa, M; Ueno, T | 2 |
| Fujioka, SI; Hagihara, H; Hashimoto, N; Ikeda, F; Iwasaki, Y; Kariyama, K; Kawaguchi, M; Kobashi, H; Kubota, J; Miyatake, H; Mori, C; Morimoto, Y; Moriya, A; Okada, H; Sakaguchi, K; Takaguchi, K; Takaki, A; Takayama, H; Takeuchi, Y; Wada, N; Yasunaka, T | 1 |
| Fukuhara, T; Furusho, N; Harada, N; Ikegami, T; Itoh, S; Kato, M; Maehara, Y; Shimoda, S; Soejima, Y; Yoshizumi, T | 1 |
| Chen, P; Liu, Q; Ma, A | 1 |
| Imai, Y; Inao, M; Kouyama, JI; Mochida, S; Motoya, D; Naiki, K; Nakao, M; Nakayama, N; Sugawara, K; Tomiya, T; Uchida, Y | 1 |
| Jang, JW; Kim, HS; Kim, JH; Kim, SB; Kim, SH; Ko, SY; Kwon, JH; Lee, BS; Lee, SH; Lee, TH; Song, DS; Song, MJ | 1 |
| Jung, BH; Lee, SG; Park, JI | 1 |
| Enomoto, M; Hai, H; Kawada, N; Kumada, H; Okada, M; Tamori, A; Uchida-Kobayashi, S | 1 |
| Chen, DS; Chen, PJ; Cheng, PN; Chien, RN; Chuang, WL; Hsu, SJ; Huang, CF; Huang, JF; Huang, YH; Hung, CH; Kao, JH; Lin, CY; Liu, CH; Liu, CJ; Peng, CY; Su, CW; Yu, ML | 1 |
| Garimella, T; Li, H; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Garimella, T; Ishikawa, H; Li, H; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Garimella, T; Green, M; Osawa, M; Shiozaki, T; Ueno, T | 1 |
| Alberti, A; Angeli, E; Angelico, M; Badia, L; Belli, L; Biolato, M; Borghi, V; Calvaruso, V; Carrai, P; Craxì, A; D'Offizi, G; Fagiuoli, S; Felder, M; Grieco, A; Guaraldi, G; Lionetti, R; Mancusi, RL; Mazzarelli, C; Milazzo, L; Montalbano, M; Pasulo, L; Persico, M; Piai, G; Puoti, M; Santantonio, T; Verucchi, G; Villa, E | 1 |
| Chayama, K; Hiraoka, A; Imamura, M; Joko, K; Kudo, M; Kumada, H; Kumada, T; Michitaka, K; Nagano, T; Nakamuta, M; Ogawa, C; Okubo, H; Senoh, T; Shibata, H; Suzuki, Y; Tachi, Y; Tada, T; Takaguchi, K; Takaki, S; Toyoda, H; Tsuji, K; Tsutsui, A; Watanabe, T | 1 |
| Abe, H; Agata, R; Atsukawa, M; Itokawa, N; Kato, K; Matsumoto, Y; Shimada, N; Tsubota, A | 1 |
| Chen, J; Li, J; Lu, H; Wang, J; Xiao, H; Yang, F | 1 |
| Chen, KY; Chen, SC; Chuang, WL; Dai, CY; Hsieh, MY; Huang, CF; Huang, CI; Huang, JF; Ko, YM; Liang, PC; Lin, YH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Chung, WJ; Jang, ES; Jeong, SH; Kim, IH; Kim, KA; Kim, YS; Lee, BS; Lee, YJ | 1 |
| Abe-Chayama, H; Aikata, H; Chayama, K; Fujino, H; Hayes, CN; Imamura, M; Kawaoka, T; Miki, D; Murakami, E; Nakahara, T; Ono, A; Osawa, M; Saito, Y; Serikawa, M; Teraoka, Y; Tsuge, M; Uchida, T | 1 |
| Ariyoshi, N; Chiba, N; Fujiyoshi, M; Kato, Y; Kawauchi, A; Matsumoto, J; Nakamura, H; Sakaue, H; San, SN; Sanbe, R; Tagai, R; Yamada, H; Yanaka, S | 1 |
| Kim, JW | 1 |
| Buonomo, AR; Gentile, I; Maraolo, AE; Pinchera, B; Scotto, R; Zappulo, E | 1 |
| Huang, CF; Yu, ML | 1 |
| Arai, J; Fukumura, Y; Imai, M; Kato, J; Kojima, K; Kondo, M; Kurokawa, K; Mori, M; Ohki, T; Seki, M; Shibata, C; Tagawa, K; Takagi, K; Toda, N | 1 |
| Doi, Y; Hagiwara, H; Hikita, H; Iio, S; Imai, Y; Kai, Y; Kodama, T; Morishita, N; Sakamori, R; Tahata, Y; Takehara, T; Tamura, S; Tatsumi, T; Urabe, A; Yamada, R; Yamada, T | 1 |
| Fujisaki, K; Hashiguchi, M; Hiramine, Y; Hori, T; Ido, A; Ijuin, S; Imanaka, D; Inada, Y; Kanmura, S; Kumagai, K; Kure, T; Mawatari, S; Moriuchi, A; Oda, K; Saisyoji, A; Sakae, H; Sakurai, K; Tabu, K; Tamai, T; Taniyama, O; Toyodome, A; Uto, H | 1 |
| Deguchi, A; Fujita, K; Himoto, T; Iwama, H; Kobara, H; Masaki, T; Mimura, S; Morishita, A; Nakahara, M; Nomura, T; Oryu, M; Oura, K; Sakamoto, T; Shimotohno, K; Tadokoro, T; Takuma, K; Tani, J; Tsutsui, K; Wakita, T; Yoneyama, H | 1 |
| Chen, H; Li, C; Liang, J; Tian, J; Xiang, H | 1 |
| Lee, DH; Lee, SH; Moon, JS; Myung, HJ; Park, TY; Ryu, SH; Shin, YJ | 1 |
| Kurosaki, K; Uesawa, Y | 1 |
| Hasuike, S; Iwakiri, H; Kuroki, K; Kusumoto, K; Matsuura, Y; Mukuda, T; Nagata, K; Nakamura, K; Ochiai, T; Ozono, Y; Shimoda, K; Tsuchimochi, M | 1 |
| Hwang, SB; Kim, B; Lee, GH; Lee, SG; Lim, YS; Lyoo, KS; Nguyen, LP | 1 |
| Jang, JY; Jun, DW; Jung, YK; Kim, MY; Kim, SG; Kwon, OS; Lee, JW; Lee, SH; Park, JY; Yoo, HW | 1 |
22 review(s) available for carbamates and bms-650032
| Article | Year |
|---|---|
HCV NS5A inhibitors in development.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Daclatasvir for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Review article: the efficacy and safety of daclatasvir in the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Comparative Effectiveness Research; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Asunaprevir for hepatitis C: a safety evaluation.
Topics: Animals; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
Asunaprevir (BMS-650032) for the treatment of hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
Next-Generation Regimens: The Future of Hepatitis C Virus Therapy.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Discovery; Drug Therapy, Combination; Forecasting; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Indoles; Isoquinolines; MicroRNAs; Molecular Targeted Therapy; Nucleic Acid Synthesis Inhibitors; Protease Inhibitors; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Nonstructural Proteins | 2015 |
Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2016 |
Asunaprevir plus daclatasvir for the treatment of chronic hepatitis C virus infection.
Topics: Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2015 |
Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development.
Topics: Amides; Antiviral Agents; Benzazepines; Benzofurans; Carbamates; Cyclopropanes; Drugs, Investigational; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Quinoxalines; Sofosbuvir; Sulfonamides | 2016 |
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Immunoassay; Immunosuppressive Agents; Interferons; Interleukins; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ritonavir; Rituximab; Sensitivity and Specificity; Sulfonamides; Transfusion Reaction; Valine; Virus Activation | 2016 |
The practical management of chronic hepatitis C infection in Japan - dual therapy of daclatasvir + asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Patient Selection; Pyrrolidines; Risk Factors; Sulfonamides; Time Factors; Treatment Outcome; Valine | 2017 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
Daclatasvir/asunaprevir based direct-acting antiviral therapy ameliorate hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Cryoglobulinemia; Female; Glomerulonephritis, Membranoproliferative; Hepatitis C; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2017 |
Beclabuvir in combination with asunaprevir and daclatasvir for hepatitis C virus genotype 1 infection: A systematic review and meta-analysis.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Pharmacokinetic and pharmacodynamic evaluation of daclatasvir, asunaprevir plus beclabuvir as a fixed-dose co-formulation for the treatment of hepatitis C.
Topics: Administration, Oral; Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Pyrrolidines; Sulfonamides; Valine | 2018 |
Daclatasvir, asunaprevir and beclabuvir fixed-dose combination for patients with genotype 1 chronic hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Drug Resistance, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C.
Topics: Benzimidazoles; Carbamates; Dose-Response Relationship, Drug; Drug Interactions; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2018 |
Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C.
Topics: Antiviral Agents; Benzazepines; Carbamates; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Tablets; Treatment Outcome; Valine | 2020 |
37 trial(s) available for carbamates and bms-650032
| Article | Year |
|---|---|
Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Diarrhea; Drug Therapy, Combination; Female; Genotype; Headache; Hepacivirus; Hepatitis C; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Japan; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2012 |
Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genes, Viral; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2013 |
Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2013 |
Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir.
Topics: Adult; Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Treatment Failure; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2013 |
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Pilot Projects; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2014 |
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2014 |
Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Topics: Adult; Aged; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Young Adult | 2014 |
Emergence of resistant variants detected by ultra-deep sequencing after asunaprevir and daclatasvir combination therapy in patients infected with hepatitis C virus genotype 1.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Isoquinolines; Middle Aged; Mutant Proteins; Mutation, Missense; Pyrrolidines; Sulfonamides; Time Factors; Valine; Viral Nonstructural Proteins | 2015 |
All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2014 |
The pharmacokinetics of daclatasvir and asunaprevir administered in combination in studies in healthy subjects and patients infected with hepatitis C virus.
Topics: Adult; Antiviral Agents; Area Under Curve; Carbamates; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine; Young Adult | 2014 |
A randomized trial of daclatasvir in combination with asunaprevir and beclabuvir in patients with chronic hepatitis C virus genotype 4 infection.
Topics: Adult; Antiviral Agents; Benzazepines; Carbamates; Drug Monitoring; Drug Resistance, Viral; Enzyme Inhibitors; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2015 |
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.
Topics: Adult; Aged; Antiviral Agents; Carbamates; DNA, Viral; Drug Administration Schedule; Drug Carriers; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2015 |
Single- and multiple-ascending dose studies to evaluate the safety, tolerability, and pharmacokinetics of daclatasvir and asunaprevir in healthy male Japanese subjects.
Topics: Administration, Oral; Adult; Antiviral Agents; Asian People; Carbamates; Double-Blind Method; Drug Administration Schedule; Healthy Volunteers; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2015 |
Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.
Topics: Adult; Aged; Alanine Transaminase; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2015 |
Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Valine; Viral Load | 2015 |
Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2015 |
Immunological Analysis During Interferon-Free Therapy for Chronic Hepatitis C Virus Infection Reveals Modulation of the Natural Killer Cell Compartment.
Topics: Antiviral Agents; Carbamates; Case-Control Studies; Cytokines; Gene Expression Regulation; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Killer Cells, Natural; Middle Aged; Pyrrolidines; Receptors, Immunologic; RNA, Viral; Sulfonamides; T-Lymphocytes; Valine; Viral Load | 2016 |
Randomized comparison of daclatasvir + asunaprevir versus telaprevir + peginterferon/ribavirin in Japanese hepatitis C virus patients.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepatitis C; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2016 |
Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients.
Topics: Adult; Aged; Antiviral Agents; Benzazepines; Carbamates; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis.
Topics: Alanine Transaminase; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2016 |
Safety and efficacy of dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney Failure, Chronic; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Sulfonamides; Treatment Outcome; Valine | 2016 |
A phase 3, open-label study of daclatasvir plus asunaprevir in Asian patients with chronic hepatitis C virus genotype 1b infection who are ineligible for or intolerant to interferon alfa therapies with or without ribavirin.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Middle Aged; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study.
Topics: Administration, Oral; Adult; Aged; Alanine Transaminase; Antiviral Agents; Asian People; Carbamates; Double-Blind Method; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; International Cooperation; Isoquinolines; Logistic Models; Male; Middle Aged; Multivariate Analysis; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Load; Viral Nonstructural Proteins | 2016 |
Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Mutation; Pyrrolidines; Simeprevir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2017 |
Daclatasvir/asunaprevir/beclabuvir fixed-dose combination in Japanese patients with HCV genotype 1 infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzazepines; Carbamates; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Safety and efficacy of dual therapy with daclatasvir and asunaprevir for older patients with chronic hepatitis C.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Predictive Value of Tests; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2017 |
Efficacy and safety of 3-week response-guided triple direct-acting antiviral therapy for chronic hepatitis C infection: a phase 2, open-label, proof-of-concept study.
Topics: Administration, Oral; Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorenes; Follow-Up Studies; Hepatitis C, Chronic; Humans; Imidazoles; Intention to Treat Analysis; Isoquinolines; Male; Middle Aged; Proof of Concept Study; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2016 |
Short-duration treatment for chronic hepatitis C virus with daclatasvir, asunaprevir, beclabuvir and sofosbuvir (FOURward study).
Topics: Adult; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; Valine; Viral Load; Young Adult | 2017 |
The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings.
Topics: Administration, Oral; Aged; Alanine Transaminase; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Logistic Models; Male; Middle Aged; Pyrrolidines; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2017 |
Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects.
Topics: Adolescent; Adult; Benzazepines; Carbamates; Cytochrome P-450 Enzyme System; Drug Combinations; Female; Healthy Volunteers; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pharmaceutical Preparations; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2018 |
Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pilot Projects; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Valine; Viral Load | 2018 |
Exposure-Response (Efficacy) Analysis of Daclatasvir and Asunaprevir in Japanese Patients With Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Serum asunaprevir concentrations showing correlation with the extent of liver fibrosis as a factor inducing liver injuries in patients with genotype-1b hepatitis C virus receiving daclatasvir plus asunaprevir therapy.
Topics: Adult; Aged; Antigens, Neoplasm; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Membrane Glycoproteins; Middle Aged; Protease Inhibitors; Protein Isoforms; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine; Young Adult | 2018 |
Efficacy and Safety of Daclatasvir and Asunaprevir in Patients with Hepatitis C Virus Genotype 1b Infection on Hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Ribavirin; RNA, Viral; Sulfonamides; Sustained Virologic Response; Taiwan; Valine; Viral Nonstructural Proteins | 2019 |
Exposure-Response Analysis for Efficacy of Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Patients.
Topics: Adult; Aged; Amino Acid Substitution; Benzazepines; Carbamates; Drug Combinations; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Logistic Models; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2019 |
129 other study(ies) available for carbamates and bms-650032
| Article | Year |
|---|---|
Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.
Topics: 3' Untranslated Regions; Amino Acid Substitution; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Viral; Drug Therapy, Combination; Genotyping Techniques; Hepacivirus; Hepatocytes; Humans; Imidazoles; Isoquinolines; Mutation; Protease Inhibitors; Pyrrolidines; Recombination, Genetic; Sulfonamides; Valine; Viral Nonstructural Proteins | 2013 |
Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication.
Topics: Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Hepacivirus; Hepatocytes; Humans; Imidazoles; Interferon-alpha; Interferons; Interleukins; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Protein Isoforms; Pyrrolidines; Recombinant Proteins; Replicon; Sulfonamides; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Interferon free regimens for the "difficult-to-treat": are we there?
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2013 |
Selection of resistant-associated variants to the NS5A inhibitor daclatasvir: revenge of the hepatitis C virus.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2013 |
"There are decades where nothing happens; and there are weeks where decades happen"--Vladimir Ilyich Lenin.
Topics: Antiviral Agents; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2014 |
Different interaction profiles of direct-acting anti-hepatitis C virus agents with human organic anion transporting polypeptides.
Topics: Antiviral Agents; Biological Transport; Carbamates; Gene Expression; HEK293 Cells; Hepacivirus; Heterocyclic Compounds, 3-Ring; Host-Pathogen Interactions; Humans; Imidazoles; Isoquinolines; Kinetics; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Plasmids; Pyrrolidines; Recombinant Proteins; Simeprevir; Sofosbuvir; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfonamides; Transfection; Uridine Monophosphate; Valine | 2014 |
Hepatitis C beware--the end is nigh.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2014 |
Daclatasvir + asunaprevir: first global approval.
Topics: Antiviral Agents; Carbamates; Drug Approval; Drug Combinations; Drug Design; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Pyrrolidines; Sulfonamides; Valine | 2014 |
Drug-induced immunoallergic hepatitis during combination therapy with daclatasvir and asunaprevir.
Topics: Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2015 |
Multiplexed LC-MS/MS method for the simultaneous quantitation of three novel hepatitis C antivirals, daclatasvir, asunaprevir, and beclabuvir in human plasma.
Topics: Antiviral Agents; Benzazepines; Carbamates; Chromatography, Liquid; Hepacivirus; Humans; Imidazoles; Indoles; Interferons; Isoquinolines; Plasma; Pyrrolidines; Reproducibility of Results; Ribavirin; Sulfonamides; Tandem Mass Spectrometry; Valine | 2015 |
[Interferon-free treatment for patients with chronic hepatitis C].
Topics: Aged; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Protease Inhibitors; Pyrrolidines; Sulfonamides; Valine | 2015 |
[Pharmacological properties and clinical efficacy of daclatasvir (Daklinza®) and asunaprevir (Sunvepra®)].
Topics: Administration, Oral; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Valine | 2015 |
Continued progress against hepatitis C infection.
Topics: Antiviral Agents; Carbamates; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Pyrrolidines; Sulfonamides; Valine | 2015 |
Low frequency of drug-resistant virus did not affect the therapeutic efficacy in daclatasvir plus asunaprevir therapy in patients with chronic HCV genotype-1 infection.
Topics: Adult; Aged; Amino Acid Substitution; Antiviral Agents; Biomarkers; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Retreatment; Sulfonamides; Time Factors; Treatment Failure; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins | 2016 |
High Sustained Virologic Response to Daclatasvir Plus Asunaprevir in Elderly and Cirrhotic Patients with Hepatitis C Virus Genotype 1b Without Baseline NS5A Polymorphisms.
Topics: Adult; Aged; Antiviral Agents; Asian People; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Liver Cirrhosis; Middle Aged; Phosphoproteins; Polymorphism, Genetic; Pyrrolidines; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2015 |
Emergence of hepatitis C virus NS5A L31V plus Y93H variant upon treatment failure of daclatasvir and asunaprevir is relatively resistant to ledipasvir and NS5B polymerase nucleotide inhibitor GS-558093 in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Benzimidazoles; Carbamates; Drug Combinations; Drug Resistance, Multiple, Viral; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Hepatitis, Viral, Animal; Hepatocytes; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sofosbuvir; Sulfonamides; Transplantation Chimera; Treatment Failure; Valine | 2015 |
Prednisolone does not affect direct-acting antivirals against hepatitis C, but inhibits interferon-alpha production by plasmacytoid dendritic cells.
Topics: Antiviral Agents; Biomarkers; Carbamates; Cell Line, Tumor; Dendritic Cells; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferon-alpha; Isoquinolines; Liver Transplantation; Prednisolone; Pyrrolidines; Ribavirin; Sulfonamides; Valine | 2015 |
Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation.
Topics: Adult; Aged; Carbamates; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Pyrrolidines; Recurrence; Sampling Studies; Sulfonamides; Tacrolimus; Valine | 2016 |
Relationships between serum asunaprevir concentration and alanine aminotransferase elevation during daclatasvir plus asunaprevir for chronic HCV genotype 1b infection.
Topics: Aged; Aged, 80 and over; Alanine Transaminase; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Serum Albumin; Sulfonamides; Valine; Viral Load | 2016 |
Successful treatment of post-transplant hepatitis C virus cirrhosis with daclatasvir and asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Failure; Liver Transplantation; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Virus Activation | 2015 |
Raltegravir Pharmacokinetics in Patients on Asunaprevir-Daclatasvir.
Topics: Adult; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Raltegravir Potassium; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Memory re-differentiation and reduced lymphocyte activation in chronic HCV-infected patients receiving direct-acting antivirals.
Topics: Antiviral Agents; Benzazepines; Carbamates; CD3 Complex; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunologic Memory; Indoles; Isoquinolines; Killer Cells, Natural; Lymphocyte Activation; Pyrrolidines; Receptors, Immunologic; Sulfonamides; Valine; Viral Load | 2015 |
Cost Effectiveness of Daclatasvir/Asunaprevir Versus Peginterferon/Ribavirin and Protease Inhibitors for the Treatment of Hepatitis c Genotype 1b Naïve Patients in Chile.
Topics: Antiviral Agents; Carbamates; Chile; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Probability; Protease Inhibitors; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2015 |
Combination therapies with daclatasvir and asunaprevir on NS3-D168 mutated HCV in human hepatocyte chimeric mice.
Topics: Animals; Antiviral Agents; Carbamates; Chimera; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Hepatocytes; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Pyrrolidines; Sulfonamides; Valine | 2016 |
Comparison of Daclatasvir and Asunaprevir for Chronic HCV 1b Infection with Telaprevir and Simeprevir plus Peginterferon and Ribavirin, with a Focus on the Prevention of Occurrence and Recurrence of Hepatocellular Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Japan; Liver Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligopeptides; Polyethylene Glycols; Polymerase Chain Reaction; Prognosis; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA, Viral; Simeprevir; Sulfonamides; Valine; Viral Load | 2015 |
Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cell Degranulation; Cells, Cultured; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Phosphorylation; Pyrrolidines; Retreatment; Ribavirin; Signal Transduction; STAT1 Transcription Factor; Sulfonamides; Sustained Virologic Response; TNF-Related Apoptosis-Inducing Ligand; Valine; Viral Load | 2017 |
Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Renal Dialysis; Renal Insufficiency; Sulfonamides; Valine | 2016 |
Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2016 |
[Daclatasvir plus asunaprevir combination therapy for patients with chronic hepatitis C].
Topics: Carbamates; Clinical Trials as Topic; Combined Modality Therapy; Drug Combinations; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2015 |
Sustained virological response after a 17-day treatment with daclatasvir plus asunaprevir in a cirrhotic patient with hepatitis C virus genotype 1b and null response for peginterferon ribavirin therapy.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Administration Schedule; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Middle Aged; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Failure; Valine; Viral Load | 2016 |
Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Carbamates; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Iron Deficiencies; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2016 |
Effect and Safety of Daclatasvir-Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b -Infected Patients on Hemodialysis.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Renal Dialysis; RNA, Viral; Sulfonamides; Valine | 2016 |
Drug-induced lung injury associated with combination therapy of daclatasvir and asunaprevir: The first case report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lung Diseases; Male; Middle Aged; Prednisolone; Pyrrolidines; Radiography, Thoracic; Sulfonamides; Tomography, X-Ray Computed; Valine | 2016 |
Application of Static Models to Predict Midazolam Clinical Interactions in the Presence of Single or Multiple Hepatitis C Virus Drugs.
Topics: Algorithms; Antiviral Agents; Benzazepines; Biotransformation; Carbamates; Cells, Cultured; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Hepatocytes; Humans; Imidazoles; Indoles; Isoquinolines; Kinetics; Liver; Midazolam; Models, Biological; Nonlinear Dynamics; Pyrrolidines; Risk Assessment; Risk Factors; RNA, Messenger; Sulfonamides; Valine | 2016 |
Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Asian People; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Daclatasvir plus Asunaprevir Treatment for Real-World HCV Genotype 1-Infected Patients in Japan.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine; Viral Nonstructural Proteins | 2016 |
Impact of Pre-existing NS5A-L31 or -Y93H Minor Variants on Response Rates in Patients Infected with HCV Genotype-1b Treated with Daclatasvir/Asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2016 |
A case of acute hepatitis B in a chronic hepatitis C patient after daclatasvir and asunaprevir combination therapy: hepatitis B virus reactivation or acute self-limited hepatitis?
Topics: Acute Disease; Aged, 80 and over; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Female; Hepatitis B; Hepatitis B virus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine; Virus Activation | 2016 |
Impact of resistance-associated variant dominancy on treatment in patients with HCV genotype 1b receiving daclatasvir/asunaprevir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Genotyping Techniques; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Prospective Studies; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
Efficacy and safety of daclatasvir and asunaprevir for hepatitis C virus genotype 1b infection.
Topics: Aged; Alanine Transaminase; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Retrospective Studies; RNA, Viral; Sulfonamides; Treatment Outcome; Valine | 2016 |
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Topics: Antigens, Neoplasm; Antiviral Agents; Biomarkers, Tumor; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Early Diagnosis; Female; Glycoproteins; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Membrane Glycoproteins; Plant Lectins; Pyrrolidines; Sulfonamides; Valine | 2016 |
Real-world efficacy and safety of daclatasvir and asunaprevir therapy for hepatitis C virus-infected cirrhosis patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2017 |
Treatment of HCV patients on hemodialysis with daclatasvir and asunaprevir.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Renal Dialysis; Sulfonamides; Treatment Outcome; Valine | 2017 |
[Combined therapy with daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b: a case report].
Topics: Adult; Antiviral Agents; Carbamates; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Valine | 2016 |
Protease Inhibitor Resistance Remains Even After Mutant Strains Become Undetectable by Deep Sequencing.
Topics: Animals; Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Interferons; Isoquinolines; Mice, SCID; Protease Inhibitors; Pyrrolidines; Simeprevir; Sulfonamides; Treatment Failure; Valine | 2016 |
Liver Fibrosis and Body Mass Index Predict Hepatocarcinogenesis following Eradication of Hepatitis C Virus RNA by Direct-Acting Antivirals.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon Type I; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Oligopeptides; Pyrrolidines; Ribavirin; Risk Factors; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2016 |
Successful treatment of three patients with human immunodeficiency virus and hepatitis C virus genotype 1b co-infection by daclatasvir plus asunaprevir.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Coinfection; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Kidney; Longitudinal Studies; Male; Pyrrolidines; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2017 |
Complex Pattern of Resistance-Associated Substitutions of Hepatitis C Virus after Daclatasvir/Asunaprevir Treatment Failure.
Topics: Aged; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Treatment Outcome; Valine | 2016 |
Pre-Existing HCV Variants Resistant to DAAs and Their Sensitivity to PegIFN/RBV in Chinese HCV Genotype 1b Patients.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Asian People; Base Sequence; Carbamates; China; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Ribavirin; RNA Helicases; Sequence Analysis, DNA; Serine Endopeptidases; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Young Adult | 2016 |
Real World Data of Daclatasvir and Asunaprevir Combination Therapy for HCV Genotype 1b Infection in Patients With Renal Dysfunction.
Topics: Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Genotype; Hepacivirus; Hepatitis C, Chronic; Hospitals, University; Humans; Imidazoles; Isoquinolines; Japan; Pyrrolidines; Renal Insufficiency; Sulfonamides; Treatment Outcome; Valine | 2017 |
A profiling study of a newly developed HCVcc strain PR63cc's sensitivity to direct-acting antivirals.
Topics: Adenosine; Antiviral Agents; Carbamates; Drug Discovery; Drug Resistance, Viral; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Mutation; Pyrrolidines; Sofosbuvir; Sulfonamides; Valine | 2017 |
Addition of ribavirin to daclatasvir plus asunaprevir for chronic hepatitis C 1b patients with baseline NS5A resistance-associated variants improved response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Polymorphism, Genetic; Pyrrolidines; Ribavirin; Sulfonamides; Taiwan; Valine; Viral Load; Viral Nonstructural Proteins | 2017 |
Identification of Genotype 2 HCV in Serotype-1 Hepatitis C Patients Unresponsive to Daclatasvir plus Asunaprevir Treatment.
Topics: Adult; Aged; Aged, 80 and over; Base Sequence; Carbamates; Disease Progression; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Phylogeny; Pyrrolidines; Serotyping; Sulfonamides; Time Factors; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
New resistance-associated substitutions and failure of dual oral therapy with daclatasvir and asunaprevir.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sex Factors; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Baseline quasispecies selection and novel mutations contribute to emerging resistance-associated substitutions in hepatitis C virus after direct-acting antiviral treatment.
Topics: Animals; Anti-Retroviral Agents; Carbamates; Drug Resistance, Viral; Evolution, Molecular; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Mice; Mutation; Phylogeny; Pyrrolidines; Selection, Genetic; Sulfonamides; Valine | 2017 |
Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: Real-world data.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Severity of Illness Index; Sulfonamides; Treatment Outcome; Valine | 2017 |
Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Exanthema; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; RNA, Viral; Sulfonamides; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2017 |
Improvement of liver stiffness in patients with hepatitis C virus infection who received direct-acting antiviral therapy and achieved sustained virological response.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Elasticity; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Male; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2017 |
Evolution of multi-drug resistant HCV clones from pre-existing resistant-associated variants during direct-acting antiviral therapy determined by third-generation sequencing.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Multiple; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Imidazoles; Isoquinolines; Male; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Daclatasvir/asunaprevir/beclabuvir, all-oral, fixed-dose combination for patients with chronic hepatitis C virus genotype 1.
Topics: Adult; Aged; Aged, 80 and over; Benzazepines; Carbamates; Cohort Studies; Drug Combinations; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Russia; Sulfonamides; Taiwan; Treatment Outcome; Valine; Young Adult | 2017 |
Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b.
Topics: Aged; Aged, 80 and over; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Linear Models; Lipid Metabolism; Lipids; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Comparison of direct sequencing and Invader assay for Y93H mutation and response to interferon-free therapy in hepatitis C virus genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Predictive Value of Tests; Pyrrolidines; Sequence Analysis; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Long-Term Follow-Up of Resistance-Associated Substitutions in Hepatitis C Virus in Patients in Which Direct Acting Antiviral-Based Therapy Failed.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Male; Middle Aged; Polyethylene Glycols; Protease Inhibitors; Pyrrolidines; Recombinant Proteins; Ribavirin; Serine Proteases; Simeprevir; Sulfonamides; Time Factors; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Renal Dialysis; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Effective Treatment With Daclatasvir and Asunaprevir in Kidney Transplant Patients Infected With Hepatitis C Virus: A Report of Two Cases.
Topics: Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunosuppressive Agents; Interferons; Isoquinolines; Kidney Transplantation; Male; Middle Aged; Prednisolone; Prospective Studies; Pyrrolidines; Ribavirin; Sulfonamides; Treatment Outcome; Valine | 2017 |
Oral Direct Acting Antivirals treatment failed to cure a patient with chronic hepatitis C due to shifts of viral genotype.
Topics: Administration, Oral; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Substitution; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2017 |
Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan.
Topics: Aged; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Protease Inhibitors; Pyrrolidines; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2017 |
The risks of hepatocellular carcinoma development after HCV eradication are similar between patients treated with peg-interferon plus ribavirin and direct-acting antiviral therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferon-alpha; Isoquinolines; Kaplan-Meier Estimate; Liver Neoplasms; Middle Aged; Proportional Hazards Models; Pyrrolidines; Ribavirin; Risk Factors; Sulfonamides; Treatment Outcome; Valine; Viral Load; Young Adult | 2017 |
The Real-World Safety and Efficacy of Daclatasvir and Asunaprevir for Elderly Patients.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Base Sequence; Carbamates; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Prevalence; Pyrrolidines; Republic of Korea; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2017 |
Direct Acting Antiviral Agents in Korean Patients with Chronic Hepatitis C and Hemophilia Who Are Treatment-Naïve or Treatment-Experienced.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Female; Fluorenes; Genotype; Hemophilia A; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2017 |
Asunaprevir and daclatasvir for recurrent hepatitis C after liver transplantation: A Japanese multicenter experience.
Topics: Adult; Aged; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Japan; Liver Transplantation; Male; Middle Aged; Postoperative Complications; Prognosis; Protease Inhibitors; Pyrrolidines; Recurrence; Risk Factors; Sulfonamides; Valine | 2017 |
Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1b.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver; Longitudinal Studies; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Topics: Aged; Animals; Antiviral Agents; Benzazepines; Carbamates; Disease Models, Animal; Female; Gene Expression Regulation; Hepacivirus; Hepatitis C, Chronic; Hepatocytes; Humans; Imidazoles; Immunity, Innate; Indoles; Inflammation; Isoquinolines; Liver; Male; Mice; Middle Aged; Pyrrolidines; Sulfonamides; Valine | 2017 |
Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Proportional Hazards Models; Pyrrolidines; Risk Factors; Sulfonamides; Sustained Virologic Response; Tomography, X-Ray Computed; Valine | 2017 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Association between alanine aminotransferase elevation and UGT1A1*6 polymorphisms in daclatasvir and asunaprevir combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Biomarkers; Carbamates; Chemical and Drug Induced Liver Injury; Drug Therapy, Combination; Female; Genetic Predisposition to Disease; Glucuronosyltransferase; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Polymorphism, Single Nucleotide; Pyrrolidines; Sulfonamides; Valine | 2018 |
Daclatasvir and asunaprevir treatment in patients infected by genotype 1b of hepatitis C virus with no or subtle resistant associated substitutions (RAS) in NS5A-Y93.
Topics: Aged; Antiviral Agents; Carbamates; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Mutation, Missense; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Rapid Changes in Serum Lipid Profiles during Combination Therapy with Daclatasvir and Asunaprevir in Patients Infected with Hepatitis C Virus Genotype 1b.
Topics: Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Monitoring; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Valine | 2018 |
HCV kinetic and modeling analyses project shorter durations to cure under combined therapy with daclatasvir and asunaprevir in chronic HCV-infected patients.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kinetics; Pyrrolidines; Sulfonamides; Valine | 2017 |
Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.
Topics: Aged; Amino Acid Sequence; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Isoquinolines; Liver Cirrhosis; Phylogeny; Polymerase Chain Reaction; Pyrrolidines; Recurrence; RNA, Viral; Sequence Homology, Amino Acid; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno.
Topics: Antiviral Agents; Carbamates; Chile; Cohort Studies; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Polyethylene Glycols; Protease Inhibitors; Public Health; Pyrrolidines; Recombinant Proteins; Ribavirin; Sulfonamides; Valine | 2017 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine | 2018 |
Case of psoriatic patient who maintains long-term remission after anti-hepatitis C virus agents and ustekinumab treatment.
Topics: Aged; Antiviral Agents; Carbamates; Dermatologic Agents; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Psoriasis; Pyrrolidines; Remission Induction; RNA, Viral; Severity of Illness Index; Sulfonamides; Ustekinumab; Valine | 2018 |
Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety.
Topics: Adult; Aged; Antiviral Agents; Biomarkers; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Liver Cirrhosis; Male; Middle Aged; Prospective Studies; Protease Inhibitors; Pyrrolidines; Retrospective Studies; Sulfonamides; Treatment Outcome; Valine | 2018 |
Cost Effectiveness of Daclatasvir Plus Asunaprevir Therapy for Chinese Patients with Chronic Hepatitis C Virus Genotype 1b.
Topics: Adult; Antiviral Agents; Carbamates; China; Cost-Benefit Analysis; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Protease Inhibitors; Pyrrolidines; Quality-Adjusted Life Years; Sulfonamides; Valine | 2018 |
Potent viral suppression and improvements in alpha-fetoprotein and measures of fibrosis in Japanese patients receiving a daclatasvir/asunaprevir/beclabuvir fixed-dose combination for the treatment of HCV genotype-1 infection.
Topics: Adult; Aged; Aged, 80 and over; alpha-Fetoproteins; Antiviral Agents; Benzazepines; Biopsy; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Liver Cirrhosis; Male; Middle Aged; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Chronic Disease; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Longitudinal Studies; Male; Middle Aged; Prospective Studies; Pyrrolidines; Quality of Life; Sulfonamides; Treatment Outcome; Valine | 2018 |
Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia.
Topics: Aged, 80 and over; Antiviral Agents; Ascites; Carbamates; Drug Therapy, Combination; Female; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Kidney Diseases; Proteinuria; Pyrrolidines; Sulfonamides; Valine | 2018 |
Cost-effectiveness of daclatasvir plus asunaprevir for chronic hepatitis C genotype 1b treatment-naïve patients in China.
Topics: Adult; Antiviral Agents; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Disease Progression; Female; Genotype; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Male; Markov Chains; Middle Aged; Monte Carlo Method; Polyethylene Glycols; Probability; Pyrrolidines; Quality of Life; Recombinant Proteins; Ribavirin; Sensitivity and Specificity; Sulfonamides; Treatment Outcome; Valine | 2018 |
Pre-emptive Treatment of HCV after Living Donor Liver Transplantation with Direct-Acting Antiviral Agents.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Graft Survival; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Polyethylene Glycols; Pyrrolidines; Recombinant Proteins; Retrospective Studies; Secondary Prevention; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine | 2018 |
Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Direct-Acting Antiviral Therapy.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Cohort Studies; Drug Therapy, Combination; Female; Gene Expression; Hepatitis C; Humans; Imidazoles; Immunity, Innate; Isoquinolines; Killer Cells, Natural; Male; Middle Aged; Pyrrolidines; RNA, Messenger; Sulfonamides; Treatment Outcome; Valine | 2018 |
Evolution and persistence of resistance-associated substitutions of hepatitis C virus after direct-acting antiviral treatment failures.
Topics: Aged; Antiviral Agents; Carbamates; Cell Line, Tumor; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Mutation; Pyrrolidines; RNA, Viral; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins; Virus Assembly; Virus Replication | 2018 |
Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world.
Topics: Aged; Antiviral Agents; Carbamates; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2019 |
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in China.
Topics: Antiviral Agents; Carbamates; China; Cost-Benefit Analysis; Drug Therapy, Combination; Genotype; Health Expenditures; Health Resources; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Life Expectancy; Male; Markov Chains; Models, Econometric; Pyrrolidines; Quality-Adjusted Life Years; Sulfonamides; Valine | 2018 |
Safety and effectiveness of daclatasvir and asunaprevir dual therapy in patients with genotype 1 chronic hepatitis C: results from postmarketing surveillance in Japan.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antiviral Agents; Body Mass Index; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Kidney; Liver Cirrhosis; Male; Middle Aged; Product Surveillance, Postmarketing; Pyrrolidines; Sex Factors; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2018 |
Limitations of daclatasvir/asunaprevir plus beclabuvir treatment in cases of NS5A inhibitor treatment failure.
Topics: Animals; Antiviral Agents; Benzazepines; Biomarkers; Carbamates; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Mice; Protease Inhibitors; Pyrrolidines; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins; Viremia | 2018 |
Late relapse of hepatitis C virus in patients with sustained virological response after daclatasvir and asunaprevir therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Isoquinolines; Male; Middle Aged; Pyrrolidines; Recurrence; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Young Adult | 2018 |
Population Pharmacokinetic Analysis for Daclatasvir and Asunaprevir in Japanese Subjects With Chronic Hepatitis C Virus Infection.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Liver Cirrhosis; Male; Middle Aged; Models, Biological; Pyrrolidines; Sulfonamides; Valine | 2018 |
Mixed HCV Infection of Genotype 1B and Other Genotypes Influences Non-response during Daclatasvir + Asunaprevir Combination Therapy.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine; Young Adult | 2018 |
Serum Asunaprevir and Daclatasvir Concentrations and Outcomes in Patients with Recurrent Hepatitis C Who Have Undergone Living Donor Liver Transplantation.
Topics: Aged; Antiviral Agents; Carbamates; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppressive Agents; Isoquinolines; Liver Transplantation; Living Donors; Male; Middle Aged; Prospective Studies; Pyrrolidines; Recurrence; Sulfonamides; Tacrolimus; Time Factors; Treatment Outcome; Valine; Viral Load | 2018 |
Cost-Effectiveness of Elbasvir/Grazoprevir Versus Daclatasvir Plus Asunaprevir in Patients with Chronic Hepatitis C Virus Genotype 1b Infection in China.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Benzofurans; Carbamates; China; Cohort Studies; Cost-Benefit Analysis; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2018 |
Successful Treatment of Fibrosing Cholestatic Hepatitis With Daclatasvir and Asunaprevir After Liver Transplantation: A Case Report.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunocompromised Host; Isoquinolines; Liver Transplantation; Living Donors; Middle Aged; Pyrrolidines; Recurrence; Sulfonamides; Valine | 2018 |
Successful direct-acting antiviral treatment of three patients with genotype 2/1 recombinant hepatitis C virus.
Topics: Adult; Aged; Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; RNA; Sofosbuvir; Sulfonamides; Valine | 2019 |
Safety Exposure-Response Analysis for Daclatasvir, Asunaprevir, and Beclabuvir Combinations in HCV-Infected Subjects.
Topics: Antiviral Agents; Asian People; Benzazepines; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Male; Models, Biological; Pyrrolidines; Sulfonamides; Valine | 2019 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
Population Pharmacokinetic Analysis of Daclatasvir, Asunaprevir, and Beclabuvir Combination in HCV-Infected Subjects.
Topics: Adult; Aged; Alanine Transaminase; Algorithms; Benzazepines; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Combinations; Female; Hepatitis C; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Male; Middle Aged; Models, Theoretical; Pyrrolidines; Sulfonamides; Valine | 2019 |
Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program.
Topics: Adult; Aged; Antiviral Agents; Carbamates; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Italy; Liver Cirrhosis; Liver Function Tests; Male; Middle Aged; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzazepines; Carbamates; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Indoles; Isoquinolines; Japan; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2019 |
Single nucleotide polymorphisms associated with elevated alanine aminotransferase in patients receiving asunaprevir plus daclatasvir combination therapy for chronic hepatitis C.
Topics: Adult; Aged; Aged, 80 and over; Alanine Transaminase; Carbamates; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Japan; Male; Middle Aged; Multivariate Analysis; Polymorphism, Single Nucleotide; Pyrrolidines; Sulfonamides; Up-Regulation; Valine | 2019 |
Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
Topics: Adult; Antiviral Agents; Carbamates; CD4 Lymphocyte Count; Coinfection; Drug Therapy, Combination; Hemophilia A; Hepacivirus; Hepatitis C; HIV Infections; HIV-1; Humans; Imidazoles; Interferons; Isoquinolines; Male; Middle Aged; Pyrrolidines; Retrospective Studies; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir.
Topics: Aged; Carbamates; Female; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Sulfonamides; Valine; Viral Load | 2020 |
Real-life effectiveness and safety of the daclatasvir/asunaprevir combination therapy for genotype 1b chronic hepatitis C patients: An emphasis on the pretreatment NS5A resistance-associated substitution test.
Topics: Aged; Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Republic of Korea; Retrospective Studies; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Ribavirin induces hepatitis C virus genome mutations in chronic hepatitis patients who failed to respond to prior daclatasvir plus asunaprevir therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Benzimidazoles; Carbamates; Cell Line; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genome, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Valine | 2020 |
Effect of CYP3A5*3 genetic variant on the metabolism of direct-acting antivirals in vitro: a different effect on asunaprevir versus daclatasvir and beclabuvir.
Topics: Antiviral Agents; Benzazepines; Carbamates; Chromatography, Liquid; Cytochrome P-450 CYP3A; Genetic Variation; Genotype; Humans; Imidazoles; Indoles; Isoquinolines; Liver; Microsomes, Liver; Pyrrolidines; Recombinant Proteins; Sulfonamides; Tandem Mass Spectrometry; Valine | 2020 |
What is the Long-term Benefit of Direct-acting Antiviral Therapy in Chronic Hepatitis C?
Topics: Antiviral Agents; Carbamates; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Valine | 2019 |
Daclatasvir plus asunaprevir in the treatment of uremic patients with chronic hepatitis C genotype 1b infection.
Topics: Carbamates; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Renal Insufficiency, Chronic; Sulfonamides; Valine | 2020 |
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.
Topics: Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Fatal Outcome; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Male; Neoplasm Recurrence, Local; Pyrrolidines; Radiofrequency Ablation; Recurrence; Sulfonamides; Valine; Viral Load | 2020 |
Pre-existing minor variants with NS5A L31M/V-Y93H double substitution are closely linked to virologic failure with asunaprevir plus daclatasvir treatment for genotype 1b hepatitis C virus infection.
Topics: Aged; Antiviral Agents; Carbamates; Case-Control Studies; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Male; Mutation; Pyrrolidines; Sulfonamides; Sustained Virologic Response; Treatment Failure; Valine; Viral Nonstructural Proteins | 2020 |
Hypovascular tumors developed into hepatocellular carcinoma at a high rate despite the elimination of hepatitis C virus by direct-acting antivirals.
Topics: Aged; alpha-Fetoproteins; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Proportional Hazards Models; Pyrrolidines; Risk Factors; Sulfonamides; Sustained Virologic Response; Valine | 2020 |
Identification of microRNA associated with the elimination of hepatitis C virus genotype 1b by direct-acting antiviral therapies.
Topics: Amides; Antiviral Agents; Benzofurans; Biomarkers; Carbamates; Cyclopropanes; Disease Eradication; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; MicroRNAs; Oligonucleotide Array Sequence Analysis; Pyrrolidines; Quinoxalines; Sulfonamides; Valine | 2021 |
Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.
Topics: Alanine Transaminase; Amides; Antiviral Agents; Aspartate Aminotransferases; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Male; Middle Aged; Pyrrolidines; Quinoxalines; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2020 |
Retreatment of Chronic Hepatitis C Failed to Daclatasvir Plus Asunaprevir by Other Direct-acting Antivirals.
Topics: Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Pyrrolidines; Retreatment; Sulfonamides; Valine | 2021 |
Molecular Initiating Events Associated with Drug-Induced Liver Malignant Tumors: An Integrated Study of the FDA Adverse Event Reporting System and Toxicity Predictions.
Topics: Adverse Drug Reaction Reporting Systems; Carbamates; Chemical and Drug Induced Liver Injury; Databases, Factual; Forecasting; Humans; Imidazoles; Isoquinolines; Liver Neoplasms; Protease Inhibitors; Pyrrolidines; Receptors, Calcitriol; Receptors, Estrogen; Sulfonamides; United States; United States Food and Drug Administration; Valine | 2021 |
Frailty Status Predicts New Long-term Care Insurance Certification in Hepatitis C Patients Receiving Antiviral Therapy.
Topics: Aged; Aged, 80 and over; Antiviral Agents; Carbamates; Eligibility Determination; Female; Frailty; Hepatitis C; Humans; Imidazoles; Insurance, Long-Term Care; Isoquinolines; Japan; Male; Pyrrolidines; Sulfonamides; Valine | 2021 |
Asunaprevir, a Potent Hepatitis C Virus Protease Inhibitor, Blocks SARS-CoV-2 Propagation.
Topics: Animals; Antiviral Agents; Carbamates; Cell Line; Chlorocebus aethiops; COVID-19 Drug Treatment; DNA-Directed RNA Polymerases; HEK293 Cells; Hepacivirus; Humans; Imidazoles; Isoquinolines; Pyrrolidines; SARS-CoV-2; Sofosbuvir; Sulfonamides; Valine; Vero Cells; Viral Nonstructural Proteins; Viral Protease Inhibitors; Virus Replication | 2021 |
Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents.
Topics: Administration, Oral; Aged; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Hepatitis C, Chronic; Humans; Imidazoles; Incidence; Interferons; Isoquinolines; Liver Cirrhosis; Liver Neoplasms; Male; Middle Aged; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Seoul; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine | 2022 |